Please login to the form below

Not currently logged in
Email:
Password:

Avandia

This page shows the latest Avandia news and features for those working in and with pharma, biotech and healthcare.

Takeda and Zinfandel abandon Alzheimer’s drug

Takeda and Zinfandel abandon Alzheimer’s drug

In 2010 GlaxoSmithKline went down the same path with its Avandia (rosiglitazone) product, although its failed trial used a different biomarker to determine risk based on cerebrospinal fluid sampling.

Latest news

  • AstraZeneca and its diabetes plans AstraZeneca and its diabetes plans

    When this is put to Boulton, he says: “ I can see where the concern comes from; ten years ago we had metformin, sulphonylureas, insulin and [GSK's type II medicine] Avandia. “

  • AZ's Onglyza may increase mortality, says FDA AZ's Onglyza may increase mortality, says FDA

    The requirement was introduced in the build-up to the withdrawal of GlaxoSmithKline's Avandia (rosiglitazone) from the European market - as well as the imposition of prescribing restrictions in the US -

  • GSK to hire doctors as product champions GSK to hire doctors as product champions

    and Wellbutrin (bupropion) and a failure to report safety data for diabetes drug Avandia (rosiglitazone).

  • FDA to review safety of AZ's saxagliptin FDA to review safety of AZ's saxagliptin

    studies. The requirement was introduced in the build-up to the withdrawal of GlaxoSmithKline's Avandia (rosiglitazone) from the European market and restriction in the US on concerns of cardiovascular toxicity. ... The restricted licence for Avandia in

  • GSK's diabetes drug among CHMP recommendations GSK's diabetes drug among CHMP recommendations

    The drug marks GSK's return to the massive diabetes market following severe restrictions in the US and suspension in the EU for its previous type 2 diabetes product Avandia (rosiglitazone)

More from news
Approximately 3 fully matching, plus 131 partially matching documents found.

Latest Intelligence

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    This has been a consequence of the safety concerns over GlaxoSmithKline's Avandia (rosiglitazone) and the subsequent restrictions, which were then lifted in the US after further analysis.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics